Business Context and Reporting Period
Easterly Government Properties, Inc. filed its Form 10-K for the fiscal year ended December 31, 2022. The internally managed REIT acquires, develops and manages commercial properties leased primarily to U.S. Government agencies. At year-end, its portfolio comprised 78 wholly owned and eight joint-venture operating properties, with approximately 8.7 million leased square feet (8.2 million at Easterly’s share), and one property under development. Operating properties were 99% leased; the weighted-average remaining lease term was 10.3 years.
Financial and Operating Metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $293.6 million | $274.9 million |
| Net income | $35.6 million | $34.0 million |
| Net income attributable to Easterly | $31.5 million | $30.1 million |
| Diluted EPS | $0.34 | $0.35 |
| FFO | $129.7 million | $124.2 million |
| FFO, as Adjusted | $128.9 million | $118.0 million |
| Cash from operating activities | $125.9 million | $118.3 million |
| Cash and cash equivalents at year-end | $7.6 million | $11.1 million |
| Debt principal outstanding | $1,256.1 million | $1,211.1 million |
Rental income was $284.5 million. Interest expense, net, increased to $47.4 million from $38.6 million. At year-end, the company reported $384.4 million of available capacity under its $450 million revolving credit facility; it also had $17.3 million in cash and restricted cash combined. Debt was 93.5% fixed-rate and 6.5% variable-rate, with a weighted-average maturity of 5.6 years and weighted-average interest rate of 3.7%. The company reported compliance with debt covenants.
Material Changes Versus Prior Year
- Revenue increased $18.7 million, primarily reflecting property acquisitions, favorable lease renewals and a full year of operations from 2021 acquisitions, partly offset by dispositions.
- Expenses rose $18.2 million, including higher property operating costs, depreciation and amortization, and interest expense.
- Net income included a $13.6 million gain on sales of ten properties and a $5.5 million impairment loss on ICE–Otay. The corresponding 2021 property-sale gain was $1.3 million.
- Operating cash flow increased $7.6 million. Investing cash outflow declined to $69.1 million from $363.0 million, largely reflecting $202.4 million of net sale proceeds. Financing shifted to a $59.7 million cash outflow from a $250.2 million inflow in 2021, which included debt and equity issuance.
- FFO, as Adjusted increased to $128.9 million from $118.0 million, while diluted EPS declined to $0.34 from $0.35. Dividends declared were $1.06 per share, versus $1.05 in 2021.
Outlook, Risks and Unusual Items
Management said expected cash flows and funding sources should meet anticipated needs for the next 12 months, including debt service, tenant improvements, planned acquisitions, distributions and other obligations. The JV expected to acquire its two remaining portfolio properties during 2023. The company had one wholly owned property under development: a planned 162,000-square-foot FDA laboratory in Atlanta with a 20-year lease.
Key risks include substantial dependence on federal tenants (97.1% of annualized lease income), tenant and agency concentration, lease expirations and early-termination rights, government shutdowns or budget impasses, refinancing and interest-rate exposure, development costs, and natural disasters and climate risks. The VA, FBI and DEA together represented 53.6% of annualized lease income. Leases representing 18.4% of annualized lease income expire by the end of 2025; tenants with early termination rights accounted for 7.8% of annualized lease income at year-end. California represented 19.9% of annualized lease income.
The company sold ten properties for approximately $202.4 million net proceeds and recorded a $13.6 million gain. It recognized a $5.5 million impairment on ICE–Otay based on revised expected cash flows and a valuation using a pending offer and discounted cash flow analysis. After year-end, it repaid the $15.7 million DEA–Pleasanton mortgage and entered into three new SOFR-based swaps. No material litigation was reported. Management and the auditor concluded internal control over financial reporting was effective; the auditor issued an unqualified opinion on the financial statements.
Important Facts for Investors to Verify
- Debt maturities and refinancing plans, particularly the $164.3 million principal due in 2024 and the $160.1 million due in 2026.
- Renewal outcomes for leases expiring through 2025 and whether tenants exercise soft-term termination rights.
- Collection, occupancy and renewal trends given federal-tenant concentration and agency exposures.
- Execution, costs and funding for the FDA–Atlanta development and the JV’s two remaining acquisitions and $64.2 million remaining capital commitment.
- Assumptions supporting the ICE–Otay valuation and whether the property is sold or re-leased on expected terms.
- Cash available for distributions, the impact of future borrowing costs and equity issuance, and the sustainability of the quarterly dividend.